Podocyte injury is a major determinant of proteinuric kidney disease and the identification of potential therapeutic targets for preventing podocyte injury has clinical importance. Here, we show that histone deacetylase Sirt6 protects against podocyte injury through epigenetic regulation of Notch signaling. Sirt6 is downregulated in renal biopsies from patients with podocytopathies and its expression correlates with glomerular filtration rate. Podocytespecific deletion of Sirt6 exacerbates podocyte injury and proteinuria in two independent mouse models, diabetic nephropathy, and adriamycin-induced nephropathy. Sirt6 has pleiotropic protective actions in podocytes, including anti-inflammatory and anti-apoptotic effects, is involved in actin cytoskeleton maintenance and promotes autophagy. Sirt6 also reduces urokinase plasminogen activator receptor expression, which is a key factor for podocyte foot process effacement and proteinuria. Mechanistically, Sirt6 inhibits Notch1 and Notch4 transcription by deacetylating histone H3K9. We propose Sirt6 as a potential therapeutic target for the treatment of proteinuric kidney disease.
P odocytes are highly specialized, terminally differentiated epithelial cells that are integral components of the renal glomerular filtration barrier, which are vulnerable to a variety of injuries and as a result, they undergo a series of changes ranging from hypertrophy, detachment, autophagy to apoptosis 1 . The genetic or acquired impairment of podocytes leads to proteinuria and contributes to the development and progression of proteinuric kidney disease. As podocytes have limited ability to repair and regenerate, the extent of podocyte injury is considered as a major prognostic determinant in end-stage renal disease 2 . There is mounting evidence of podocyte injury in a variety of other renal diseases such as focal segmental glomerulosclerosis (n = 6.) Data are expressed as means ± SE. Student's t-test was employed for comparisons between two groups; one-way ANOVA followed by Tukey's post-test for multiple comparisons was used for groups of three or more (FSGS), membranous glomerulonephritis (MGN), diabetic nephropathy (DN) and IgA nephropathy. In these conditions, podocytes lose specific markers of differentiation, undergo foot process effacement and eventual detachment, and reduce the capacity to maintain the glomerular filtration barrier, thereby resulting in proteinuria 3 . Therefore, therapies aimed at preventing podocyte injury or promoting podocyte repair have major potential clinical and economic benefits. Although studies have seen dramatic advances in the understanding of podocyte biology and the pathogenesis of podocyte injury, the delivery of podocyte-specific therapies is still a great challenge. For instance, many current therapies such as glucocorticosteroids, calcineurin antagonists and mTOR inhibitors have potent effects on podocytes, but the nonspecific natures of these agents lead to undesirable systemic adverse effects 1 . Therefore, identifying the key and universal molecules involved in the different forms of podocytopathies may provide clues to develop new therapeutic strategies for patients with proteinuric kidney disease. Histone deacetylases (HDACs) are enzymes that balance the acetylation activities of histone acetyltransferases on chromatin remodeling and play essential roles in the modulation of physiological and pathological gene transcription. Sirt6 is a member of the sirtuin family of class III NAD + -dependent HDACs, which consists of seven enzymes (Sirt1 to Sirt7) that share conserved core catalytic domains, but differ in their cellular localization and tissue distribution. The pleotropic identity of Sirt6 is manifested into several catalytic activities including deacetylation and ribosylation, which influence the physiology of multiple cell types and tissues. Sirt6-dependent deacetylation of H3K9 or H3K56 is required for the regulation of genes associated with glucose/lipid metabolism, DNA repair, telomerase function, genomic stability, and cellular senescence. Sirt6-deficient mice have displayed genomic instability and several phenotypes of accelerated premature aging 4 . Sirt6 also functions as a central regulator of hematopoietic stem cell homeostasis 5 and somatic growth 6 . However, the role of Sirt6 in the kidney keeps unclear.
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In this study, we found that the level of Sirt6 was reduced in renal biopsies from patients with podocytopathies and was correlated with glomerular filtration rate. Podocyte-specific deletion of Sirt6 exacerbated podocyte injury and proteinuria in two independent mouse models including DN and adriamycin (ADR)-induced nephropathy. Mechanistically, Sirt6 negatively regulated Notch signaling by the suppression of the transcription of Notch1 and Notch4 genes. Our findings suggest Sirt6 as a potential therapeutic target in proteinuric kidney disease.
Results
Sirt6 is reduced in podocytes from DN or ADR mice. We first assessed the expression patterns of SIRTs in the kidney from STZ-induced diabetic mice and ADR-treated mice (a single injection of ADR leads to significant glomerular damage that recapitulates the human disease of FSGS) individually, two independent models for proteinuric kidney disease. Our results showed that the levels of Sirt1, Sirt3, Sirt4, and Sirt6 were reduced in the kidney from STZ-induced diabetic mice. In mice with ADR nephropathy, Sirt1, Sirt5, and Sirt6 were downregulated in the kidney, but the expression of Sirt4 was shown an increase (Fig. 1a) . Considering that both Sirt1 and Sirt6 were reduced in DN and ADR nephropathy and recent studies have highlighted the contribution of Sirt1 to the regulation of renal function, this study was designed to further explore the role of Sirt6 in the kidney. The reduced Sirt6 expression was also observed in the kidney from db/db mice (Fig. 1b) immunofluorescent results showed a significant reduction of podocyte Sirt6 expression from STZ-induced diabetic mice and ADR-treated mice by double immunostaining of Sirt6 and podocyte specific markers synaptopodin (Fig. 1c) or Wilms' tumor protein-1 (WT-1) ( Supplementary Fig. 1 ). In vitro, high glucose (HG, Fig. 2d ) or advanced glycation end-products (AGE, Fig. 2e ) significantly reduced podocyte Sirt6 expression in a concentration-dependent manner. In addition, we also demonstrated the reduction of Sirt6 expression in ADR-treated podocytes (Fig. 1f) , suggesting that the decreased Sirt6 expression may HG/Ad-Sirt6 
importantly contribute to podocyte injury under different pathological conditions. We also found that other renal parenchymal cells including rat glomerular mesangial cells, rat glomerular endothelial cells, and human tubule epithelial cells (HK-2) had different expression patterns of Sirt6 in response to hyperglycemia ( Supplementary Fig. 2 ) or ADR ( Supplementary  Fig. 3 ). In addition, we also characterized the expression profile of Sirt6 in various types of renal parenchymal cells and found that Sirt6 may have different intracellular localizations in these cells ( Supplementary Fig. 4 ).
Reduction of Sirt6 in various podocytopathies renal biopsies.
We first confirmed the reduction of Sirt6 in renal biopsies from DN (n = 8) and FSGS (n = 10) subjects compared with normal subjects or diabetic patients without nephropathy (DM-NN, n = 7) by immunohistochemistry (IHC) staining ( Fig. 2a ) and real time reverse transcription (RT)-PCR analysis (Fig. 2b) . Importantly, the Sirt6 level was also markedly reduced in renal biopsies from patients with other different forms of podocytopathies such as MGN (n = 8) and IgA nephropathy (n = 9). Notably, the mRNA levels of Sirt6 were positively correlated with estimated glomerular filtration rate (estimated GFR, Fig. 2c ) and negatively correlated with proteinuria in all subjects (Fig. 2d ).
Sirt6 deletion exacerbates podocyte injury in diabetic mice. To elucidate the role of Sirt6 in podocyte homeostasis and injury in vivo, we generated conditional knockout mice in which Sirt6 is specifically ablated in podocytes by using Cre-LoxP recombination system. Podocin-Cre mice were crossed with Sirt6 fl/fl to generate Podocin-Cre Sirt6 fl/fl mice (Cre + /Sirt6 fl/fl mice), which was identified by tail genotyping (Fig. 3a) , immunofluorescent analysis in podocytes ( Fig. 3b ) and a significant reduction in the protein levels of Sirt6 in isolated glomeruli from Cre + /Sirt6 fl/fl mice ( Fig. 3c ). All mice were viable and fertile. Firstly, we analyzed Cre + /Sirt6 fl/fl mice and control mice in age-matched groups. Up to 9-month after birth, Cre + /Sirt6 fl/fl mice were indistinguishable from control littermates as analyzed by renal histology, albuminuria, and glomerular ultrastructure. In a 12-month follow-up, the ageing Cre + /Sirt6 fl/fl mice developed a slight albuminuria (Fig. 3d ), mesangial matrix expansion ( Fig. 3e ) and podocyte injury as evidenced by glomerular basement membrane (GBM) thickening, and podocyte foot process broadening and effacement ( Fig. 3f ) but significantly higher than in control mice. Moreover, we also evaluated the expression levels of other isoforms of sirtuins in isolated glomeruli from Cre + /Sirt6 fl/fl mice in vivo or Sirt6-deficient podocytes in vitro. At the expression levels, we did not find other sirtuins to compensate for Sirt6 deficiency ( Supplementary Fig. 5 ). In Supplementary Table 1 , STZ-induced diabetic mice (22-week old) had hyperglycemia and lower body weight compared with their non-diabetic counterparts, no difference in blood pressure among these groups. As shown in Fig. 4a , diabetic Cre + /Sirt6 fl/fl mice exhibited a significant increase in urinary albumin excretion as compared with diabetic Cre + /Sirt6 +/+ mice. Morphological examinations showed the glomerular mesangium expansion ( Fig. 4b ) and podocyte injury (Fig. 4c ) from diabetic Cre + /Sirt6 +/+ mice, all of which were exacerbated in diabetic Cre + /Sirt6 fl/fl mice. Podocyte injury was further confirmed by a significant loss of key podocyte differentiation markers including nephrin and podocin in diabetic Cre + /Sirt6 fl/fl mice (Fig. 4d) . In addition, considering that the expression of urokinase plasminogen activator receptor (uPAR) is induced in podocytes during proteinuric kidney disease, which is required for the development of podocyte foot process effacement and proteinuria, we further detected the uPAR expression in different groups of mice and found the low-level of uPAR expression in podocytes from control mice by immunofluorescent analysis. In contrast, diabetic Cre + /Sirt6 +/+ mice had a significant increase in podocyte uPAR expression, an even stronger induction of uPAR expression was found in podocytes from diabetic Cre + /Sirt6 fl/fl mice (Fig. 4e) .
Sirt6 has pleiotropic protective actions in podocytes. In vitro, overexpression of Sirt6 by a Sirt6-adenovirus transfection (Fig. 5a ) reduced the levels of proinflammatory mediators (Fig. 5b) , attenuated podocyte apoptosis (Fig. 5c) , and ameliorated actin cytoskeleton derangement (Fig. 5d ) in podocytes with HG treatment. In addition, overexpression of Sirt6 also reduced the expression level of uPAR in podocytes with HG treatment (Supplementary Fig. 6 ). Moreover, we observed that overexpression of Sirt6 restored autophagy in podocytes as evidenced by the increased levels of autophagy-related proteins (Fig. 5e) . Finally, we utilized the tandem RFP-GFP-LC3 adenovirus construct to confirm autophagy induction by form punctate that represent autophagosome formation. In Fig. 5f , we observed the successful introduction of the RFP-GFP-LC3 adenovirus construct showing both fluorescent proteins. In addition to accumulation of LC3, more red puncta were present in podocytes with Sirt6 overexpression than in controls under HG condition. In addition, the number of typical autophagosomes with double membranes was increased in podocytes with Sirt6 overexpression (Fig. 5g) . These results further confirmed that Sirt6 induces autophagy in podocytes.
Sirt6 inhibits Notch signaling by deacetylating H3K9.
Considering that Sirt6 is a highly specific deacetylase that targets H3K9 for the regulation of gene expression by modifying chromatin structure 7, 8 , we then measured the levels of H3K9 acetylation (H3K9ac) under pathological conditions and found that the H3K9ac levels were significantly increased in renal biopsies from patients with DN and FSGS by IHC staining (Fig. 6a) . In animal studies, a more significant increase in H3K9ac in podocytes from diabetic Cre + /Sirt6 fl/fl mice was also observed as compared with diabetic Cre + /Sirt6 +/+ mice (Fig. 6b) . In vitro, HG-induced H3K9ac was attenuated by overexpression of Sirt6 (Fig. 6c) . Moreover, we observed the changes of Notch signaling in HG-treated podocytes with or without Sirt6 overexpression by Agilent Whole Human Genome Oligo Microarray for global gene expression analysis (Fig. 6d) . Real time RT-PCR analysis found that among Notch isoforms, only Notch1 and Notch4 were upregulated in HG-treated podocytes, which could be attenuated by overexpression of Sirt6 (Fig. 6e) . The same tendency was also found in podocytes from diabetic Cre + /Sirt6 fl/fl mice as compared Fig. 7) . Mechanistically, we examined whether Sirt6 deficiency results in the increased H3K9ac in the promoters of Notch genes by chromatin immunoprecipitation (ChIP). Our results revealed the increased levels of H3K9ac in the promoters of Notch1 and Notch4 in podocytes with HG treatment (Fig. 6f) . To confirm whether Sirt6 can recruit and deacetylate H3K9 on these promoters, we performed ChIP assay in podocytes with overexpression of Sirt6 and found that Sirt6 significantly reduced the level of H3K9ac in the promoter region of Notch1 and Notch4 (Fig. 6f) . Our results further confirmed that Sirt6 could bind to the promoter of Notch1 and Notch4 (Fig. 6g) . Under HG condition, Sirt6 was dissociated from the promoters of these genes in podocytes and recruited to them after Sirt6-adenovirus transfection by ChIP analysis (Fig. 6g) . Furthermore, overexpression of Sirt6 reduced HG-induced Notch signaling downstream target genes such as HES1 and Snail1 by mRNA analysis as well as the results from podocytes treated with DAPT that is a γ-secretase inhibitor and indirectly inhibit Notch signaling pathways (Fig. 6h) , which was consistent with in vivo studies showing more significant increases in the levels of HES1 and Snail1 in podocytes from diabetic Cre + /Sirt6 fl/fl mice ( Supplementary Fig. 7 ). Moreover, we found that gene silencing of Sirt6 can regulate the basal levels of Notch1 and Notch4 in podocytes (Fig. 6i) .
Notch inhibition rescues Sirt6-deficient podocytes injury. Inhibition of Notch signaling reduced inflammatory responses (Fig. 7a) and apoptosis (Fig. 7b) , ameliorated actin cytoskeleton derangement (Fig. 7c) , and recovered the expression levels of nephrin and podocin (Fig. 7d ) in Sirt6-deficient podocytes. As well as gene silencing of Notch1 restored the levels of autophagyassociated proteins in podocytes with HG treatment (Supplementary Fig. 8 ), gene silencing of Notch1 can also restore the levels of autophagy-associated proteins (Fig. 7e ) and autophagy flux (Fig. 7f ) in Sirt6-deficient podocytes.
Sirt6 deletion exacerbates podocyte injury in ADR mice. We also utilized the murine model of ADR nephropathy to confirm the role of Sirt6 in maintaining podocyte function. ADR-treated Cre + /Sirt6 fl/fl mice exhibited significant increases in urinary albumin excretion (Fig. 8a) , glomerulosclerosis ( Fig. 8b ) and podocyte injury (Fig. 8c) , and marked decreases in the levels of nephrin and podocin (Fig. 8d ) compared with the ADR-treated Cre + /Sirt6 +/+ mice. Furthermore, we found that overexpression of Sirt6 attenuated ADR-induced podocyte apoptosis (Fig. 8e) . Sirt6 was also confirmed to regulate H3K9ac at promoters of Notch1 and Notch4 in podocytes with ADR treatment (Fig. 8f, g ). Through regulating H3K9ac at promoters of Notch1 and Notch4, Sirt6 reduced Notch1 and Notch4 transcription (Fig. 8h ). Significant increases in H3K9ac, Notch1 and Notch4 expression were also observed in podocytes from ADR Cre + /Sirt6 fl/fl mice ( Supplementary Fig. 9 ). (Fig. 9a) . Overexpression of Sirt6-significantly ameliorated renal injury as evidenced by reduced albuminuria (Fig. 9b) , decreased mesangial expansion (Fig. 9c ) and ameliorated podocyte injury (Fig. 9d) in Cre + /Sirt6 fl/fl mice with ADR treatment, as well as recovered nephrin and podocin expression (Fig. 9e) and increased the levels of LC3 and beclin1 by IHC staining (Supplementary Fig. 10 ). In addition, ChIP assay in isolated glomeruli further confirmed that overexpression of Sirt6 deacetylated H3K9ac at promoter of Notch1 (Fig. 9f, g ). Consistently, the levels of Notch1, Notch4 and H3K9ac were significantly decreased in podocytes after transfection with Sirt6 lentivirus in Cre + /Sirt6 fl/fl ADR-treated mice by immunofluorescent analysis ( Supplementary Fig. 11 ).
Discussion
Although emerging evidence have indicated the importance of epigenetic modification on the regulation of renal function 9, 10 , current understanding of biological functions of sirtuins in the kidney is very limited and their roles in epigenetic-mediated renal functions remain to be elucidated. In this study, we found that both Sirt1 and Sirt6 were downregulated in the kidney from mice with DN or ADR nephropathy, two independent models for proteinuric kidney disease. Considering that recent studies highlight the contribution of Sirt1 to the regulation of renal function [11] [12] [13] [14] , our studies was designed to further explore the functional role of Sirt6 in the kidney. Firstly, we characterized the expression profile of Sirt6 in various types of renal parenchymal cells such as rat glomerular mesangial cells, rat glomerular endothelial cells, human podocytes, and human proximal tubule epithelial cells (HK-2). It was found that Sirt6 was expressed in all these major types of renal cells. Although Sirt6 was originally identified as a nuclear-localizing protein 15 and our studies showed that Sirt6 localized in the nucleus of human podocytes, Sirt6 was also found more or less in the cytoplasm of some other renal cells by our current antibody-based molecular assays, leading us to speculate that renal Sirt6 may shuttle between the nucleus and cytoplasm, depending on cell type or environmental stimuli. One of the most important findings in this study was a significant reduction in Sirt6 expression in the kidney that was correlated with estimated GFR and the levels of proteinuria from H3K9ac) in the promoters of Notch1 and Notch4 using antibodies to H3K9ac. g ChIP analysis showed that Sirt6 bound to promoters of Notch1 and Notch4 genes by using antibodies to Sirt6 in podocytes. Sirt6 was dissociated from the promoters of these genes in podocytes with HG treatment and recruited to them after overexpression of Sirt6. *P < 0.05 vs. control, # P < 0.05 vs. scramble of HG treatment. (n = 6.) h Summarized data showing the effect of overexpression of Sirt6 or inhibition of Notch signaling by DAPT on the mRNA levels of Notch downstream genes HES1 and Snail1in podocytes treated with HG. i Representative western blot gel documents and summarized data showing Sirt6 deficiency on the effect of Notch1 and Notch4 expressions in podocytes. *P < 0.05 vs. control. (n = 6.) Data are expressed as means ± SE. Student's t-test was employed for comparisons between two groups; one-way ANOVA followed by Tukey's post-test for multiple comparisons was used for groups of three or more patients with different types of podocytopathies, suggesting that the reduction of Sirt6 may be a common feature of human proteinuric kidney disease. To explore the role of Sirt6 on the regulation of podocyte function, we established podocyte-specific Sirt6 knockout (Cre + /Sirt6 fl/fl ) mice and renal injury was induced by STZ and ADR individually. The increases in urinary albumin excretion and the severity of glomerular injury were all significantly greater in Cre + /Sirt6 fl/fl mice than in control mice, indicating that Sirt6 as a central target molecule protects against podocyte injury. Functionally, except that Sirt6 had pleiotropic protective actions such as anti-inflammation and anti-apoptosis, we also found that Sirt6 can modulate uPAR signaling in podocytes. Studies have demonstrated uPAR can lead to foot process effacement and urinary protein loss in puromycin aminonucleoside nephrosis and LPS-induced transient proteinuria in mice, which was also identified in a majority of patients with FSGS as a soluble factor that acts through binding to and activating podocyte β3 integrin to promote cell motility and kidney permeability 16, 17 . In addition, studies have showed that nuclear factor of activated T cells (NFAT) 2 inhibitor ameliorates DN and podocyte injury in db/db mice by inhibiting the expression of uPAR 18 . In this study, we found that Cre + /Sirt6 fl/fl diabetic mice exhibited a marked increase in the level of uPAR as compared with the Cre + /Sirt6 +/+ diabetic mice, indicating that Sirt6 may be one of the critical components that links uPAR to podocyte injury in the pathogenesis of DN.
Emerging evidence has indicated that impaired autophagic activity is involved in the development of chronic kidney disease 19 . Podocytes display a high level of basal autophagy, which is important for the maintenance of podocyte homeostasis 20 . Podocyte specific deletion of ATG5 leads to proteinuria and glomerulopathy in aging mice 19, 21 . Although mounting evidence indicates that HDAC-mediated acetylation can regulate autophagy, different isoforms have different effects on autophagy. HDAC10 promotes autophagy-mediated cell survival 22 , whereas / S ir t 6 + /+ C r e + / S ir t 6 fl /f l C r e + / S ir t 6 + /+ C r e + / S ir t 6 fl /f l C r e + / S ir t 6 + /+ C r e + / S ir t 6 fl /f l C r e + / S ir t 6 + /+ C r e + / S ir t 6 fl /f l C r e + / S ir t 6 + /+ C r e + / S ir t 6 fl /f l C r e + / S ir t 6 + /+ C r e + / S ir t 6 fl /f l C r e + / S ir t 6 + /+ C r e + / S ir t 6 fl /f l C r e + / S ir t 6 + /+ C r e + / S ir t 6 fl /f l C r e + / S ir t 6 + /+ C r e + / S ir t 6 fl /f l C r e + / S ir t 6 + /+ C r e + / S ir t 6 fl /f l HDAC4 negatively regulates podocyte autophagy 9 . Sirt1 induces autophagy during caloric restriction, which is associated with longevity 23 . In contrast, negative regulation of autophagy via Sirt1 was observed in the setting of cigarette smoke exposure 24 .
The mixed observation may result from different substrates of individual HDACs and different contributions in different pathophysiological conditions. In this study, we attempted to clarify whether Sirt6 is involved in the regulation of autophagy in podocytes. In consistent with previous studies showing the induction of autophagy via Sirt6 in human bronchial epithelial cells 25 , we found that Sirt6 positively regulated autophagy and demonstrated under pathogenic conditions, relative insufficiency of autophagy was a critical determination of podocyte injury, which was attributed to the reduced Sirt6 expression.
Considering that the changes of Notch signaling were observed in HG-treated podocytes with or without Sirt6 overexpression, and Notch signaling mediates inflammatory responses 26 , cellular apoptosis 27 and autophagy 28 , which can be regulated by epigenetic modification 29 , Notch may be a potential target of Sirt6. The Notch pathway consists of four Notch receptors (Notch1-4) and five Notch ligands including Jagged1, Jagged2, Delta-like (Dll) 1, Dll3, and Dll4. In the kidney, Notch is a critical regulator of kidney development and this pathway is mostly silenced once kidney maturation. However, Notch signaling can be reactivated under different renal pathological conditions 30 . The Notch pathway in mature podocytes plays a critical role in the development of glomerular disease 31 and can be activated by HG 32 or other stimuli 33 . Studies have observed that conditional (H3K9ac) in the promoter of Notch1 using antibodies to H3K9ac in isolated glomeruli. g ChIP analysis showed that Sirt6 bound to promoters of Notch1 by using antibodies to Sirt6 in isolated glomeruli. *P < 0.05 vs. control (vector/Cre + /Sirt6 +/+ mice), # P < 0.05 vs. vector/ADR/Cre + /Sirt6 +/+ mice, & P < 0.05 vs. vector/ADR/Cre + /Sirt6 fl/fl mice. (n = 8.) Data are expressed as means ± SE. Student's t-test was employed for comparisons between two groups; one-way ANOVA followed by Tukey's post-test for multiple comparisons was used for groups of three or more re-expression of the intracellular domain of Notch (NICD) exclusively in podocytes caused proteinuria and glomerulosclerosis. At the molecular levels, Notch signaling can induce endocytosis of nephrin, thereby triggering the onset of proteinuria 34 . Although precise mechanisms of epigenetic regulation at Notch target genes are not completely understood, emerging evidence suggests that histone modifications play a pivotal role in this process 35, 36 . In this study, we discovered a novel role of Sirt6 in Notch signaling. By binding to their promoters and deacetylating H3K9 at these sites, Sirt6 reduced the expression of Notch1 and Notch4, which was in consistent with the results showing that the levels of Notch1 and Notch4 were significantly increased in podocytes from Cre + /Sirt6 fl/fl mice with DN or ADR nephropathy. Of many Notch downstream target genes, HES1 and Snail are well characterized and mostly relevant to proteinuria in nephropathy 37 . In this study, we further found that podocyte Snail and HES1 expressions were markedly induced in response to HG and ADR, and Sirt6 substantially suppressed their induction. In addition, inhibition of the Notch pathway by pharmacological or genetic manipulation rescued the functional defect in Sirt6-deficient podocytes. We further provided direct evidence showing that overexpression of Sirt6 had therapeutic potential for ADR nephropathy through targeting Notch signaling. In this study, we cannot exclude other downstream molecules of Sirt6 may also contribute to the regulation of podocyte function. For instance, Wnt/β-catenin signaling is an evolutionarily conserved developmental signaling cascade that exhibits a pivotal function in promoting podocyte dysfunction and albuminuria in proteinuric kidney diseases 38 . Studies have demonstrated that SIRT6 controls hematopoietic stem cell homeostasis through epigenetic regulation of Wnt signaling 5 , it is possible that Sirt6-mediated Wnt signaling is also associated with the regulation of podocyte function. Therefore, it is necessary to further clarify the role of Wnt signaling as well as other potential downstream targets epigenetically regulated by Sirt6 in podocytes.
It should be noted that although we did not attempt to explore molecular mechanisms of Sirt6 regulation in podocytes under pathological conditions, recent studies have reported that Sirt6 can be regulated by post-transcriptionally at the RNA and protein levels 39 . MiR-33 and miR-122 reduce Sirt6 mRNA stability 40, 41 . The MDM2 ubiquitylate can target Sirt6 protein for proteasedependent degradation 42 . Sirt6 gene expression is also modulated by several transcription factors such as E2 transcription factor 1 (E2F1) and Runt-related transcription factor 2 (RUNX2) 43, 44 . In addition, Sirt1 can regulate Sirt6 by forming a complex with FOXO3a and NRF1 on the promoter of Sirt6 45 . In fact, our preliminary studies have also found that the downregulation of Foxo3a and NRF1 in podocytes with HG treatment. Further studies are needed to clarify the precise mechanisms of Sirt6 regulation.
Collectively, our studies for the first time demonstrate that Sirt6 protects against podocyte injury and proteinuria, at least in part through epigenetic regulation of Notch signaling (Fig. 10) . Pharmacological targeting of Sirt6-mediated Notch signaling pathways at multiple levels may provide a novel approach for the treatment of proteinuric kidney disease.
Methods
Human renal biopsy samples. Renal biopsies had been performed as part of routine clinical diagnostic investigation and collected as described in Supplementary Table 2 expression were used as controls (Podocin-Cre Sirt6 +/+ ; Cre + /Sirt6 +/+ ). Genotyping by tail preparation and PCR were performed at 2 weeks of age.
STZ-induced diabetic nephropathy (DN) in mice.
Mice with a C57BL/6 background do not develop lesions of DN readily after the induction of diabetes by STZ. In addition, a high-fat diets (HFD) provides a commonly used approach to induce obesity and insulin resistance in C57BL/6 strain. In particular, after the onset of metabolic syndrome, mice on a HFD develop increased albuminuria and glomerular lesions 46, 47 . Therefore, we used a STZ-treated uninephrectomized mice model on a HFD to hasten the development of DN following previous studies 47 . To induce DN, Cre + /Sirt6 +/+ , and Cre + /Sirt6 fl/fl mice with a C57BL/6 background mice (male, 10 weeks of age) were injected STZ (80 mg per kg body weight intraperitoneally daily for 3 days). All male mice had unrestricted access to food/ water and were maintained for 12 weeks of HFD feeding in accordance with the institutional animal care and use committee procedures of Shandong University. All protocols were approved by the Institutional Animal Care and Use Committee of School of Medicine, Shandong University (Document No. LL-201501025) and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Different groups were allocated in a randomized manner and investigators were blinded to the allocation of different groups when doing surgeries and doing outcome evaluations.
Adriamycin (ADR)-induced nephropathy in mice. In the ADR model, male mice (10 weeks of age) were administered ADR (20 mg/kg) intravenously by tail vein injection 48 . Urine was collected weekly to assess for albuminuria, and mice were sacrificed 5 weeks after treatment. Different groups were allocated in a randomized manner and investigators were blinded to the allocation of different groups when doing surgeries and doing outcome evaluations.
db/db mice. Twelve-week-old male type 2 diabetic db/db mice and genetic control db/+ mice were obtained from the Jackson laboratory.
Intrarenal lentivirus delivery. After 1 day ADR injection, recombinant lentivirus vectors pGLV3-harboring Sirt6 (pGLV3-Sirt6) or their negative controls (pGLV3-null) were delivered into the mouse kidney. The procedure for lentivirus delivery was performed as described with slight modifications 49 . In anesthetized mice, after temporary occlusion of left renal pedicle, a 31G needle was inserted at the lower pole of the kidney parallel to the long axis and was carefully pushed toward the upper pole. As the needle was slowly removed, 100 µl filter-purified lentivirus cocktail (1 × 10 5 IU/µ1) or saline was injected. Preliminary studies showed that lentiviral-mediated mRNA expression in kidney parenchyma were significantly upregulated after 48 h and no toxicity was observed in rats treated with the lentiviral vector.
Transmission electron microscopy (TEM). Electron microscopic sample handling and detection were performed by the electron microscopic core lab of Shandong University as described 47 . TEM images were analyzed using Image J (National Institutes of Health, NIH, Bethesda, MD, USA). The GBM thickness, foot process width and the number of foot processes per μm of GBM were calculated using a curvimeter (SAKURAI CO., LTD, Tokyo, Japan). Five glomeruli were randomly selected from each mouse and ten electron micrographs were taken in each glomerulus.
Cell culture and treatments. Rat glomerular mesangial cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), human podocytes were originally provided by Dr Saleem MA from University of Bristol at UK, rat glomerular endothelial cells were obtained from Creative Bioarray (Shirley, NY, USA), and human tubule epithelial cells (HK-2) were obtained from ATCC. Rat glomerular mesangial cells were cultured in Dulbecco's modified Eagle's medium containing 18 mmol/l sodium bicarbonate, 25 mmol/l glucose. Human podocytes were cultured in RPMI 1640 medium containing 11.0 mmol/l glucose as described. Rat glomerular endothelial cells were maintained in RPMI 1640 containing 2000 mg/l glucose. Human tubule epithelial cells (HK-2) were cultured in a 50:50 mixture of Dulbecco's Modified Eagle's Medium/F12. Overexpression of Sirt6 by a Sirt6-adenovirus transfection was used in this study. Different stimuli were used in this study: (1) HG (a final concentration of 20 or 40 mmol/l in culture medium); (2) Advanced glycation end product (AGE, 50-200 μg/ml); (3) ADR (0.4 μg/ml) Chromatin immunoprecipitation (ChIP) assay. ChIP was performed according to the manufacturers' instructions by using Magna ChIP HiSens Kit (Millipore, Darmstadt, Germany). Chromatin samples were immunoprecipitated with antibodies against a negative control normal mouse IgG, H3K9ac or Sirt6 (Abcam, Cambridge, MA). PCR amplification was performed in 20 μl volumes for [30] [31] [32] [33] [34] [35] cycles to determine the appropriate conditions for the PCR products of each region. Primer sequences are shown in Supplementary Table 3 . Antibodies used in this study are summarized in Supplementary Table 5 .
RNA extraction and real time RT-PCR. Total RNA was isolated from mouse kidney or cells using TRIzol reagent (Invitrogen). The mRNA expression levels were determined by real-time quantitative RT-PCR using a Bio-Rad iCycler system (Bio-Rad, Hercules, CA).The sequences of specific primers are listed in Supplementary Table 4 .
Western blot and immunoprecipitation analyses. Total cellular lysates preparation and western blot analysis were performed as follows: cells were collected with RIPA buffer (150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP40, 1 mM EDTA and 50 mM Tris pH 8.0), followed by separation with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Then samples were transferred to PVDF membrane and incubated with primary antibody in 5% milk. Antibodies used in this study are summarized in Supplementary Table 5 . To document the loading controls, the membrane was reprobed with a primary antibody against housekeeping protein GAPDH. The uncropped blots were shown in Supplementary Figs. 12 and 13 .
